Questions: Insulin Resistance: Impaired Glucose Uptake, Hyperinsulinemia, and Metabolic Dysfunction

Question 1

A patient has a fasting glucose of 94 mg/dL (within normal range) but fasting insulin levels four times higher than normal. What does this most likely indicate?

• A. Type 1 diabetes, because insulin is being produced in excess to compensate for absent receptors
• B. Early insulin resistance with successful beta cell compensation — the patient has metabolic disease despite normal glucose
• C. Normal physiology; high fasting insulin is a sign of excellent glucose regulation
• D. Pancreatic hyperplasia causing overproduction of insulin independent of blood glucose

Answer: (B)

This is the hallmark of compensated insulin resistance. When peripheral tissues respond poorly to insulin, beta cells ramp up secretion — sometimes 2–5x — to force enough GLUT4 translocation to maintain near-normal glucose. Normal fasting glucose does not rule out significant metabolic disease; it just means the beta cells are still compensating. This patient is on a trajectory toward type 2 diabetes, but the disease is 'invisible' to routine glucose screening. Option C is the common misconception — high fasting insulin is not healthy; it signals a broken signaling system working overtime.

Question 2

Excess intracellular fatty acids impair insulin signaling primarily by which mechanism?

• A. Directly blocking GLUT4 channels in the plasma membrane, preventing glucose entry
• B. Competing with insulin for binding at the insulin receptor's extracellular domain
• C. Activating serine/threonine kinases (e.g., PKC) that phosphorylate IRS-1 at inhibitory serine residues, jamming the signaling cascade
• D. Triggering beta cell apoptosis, reducing insulin secretion before resistance develops

Answer: (C)

Lipid intermediates like diacylglycerol and ceramides activate PKC isoforms that phosphorylate IRS-1 at serine residues rather than the activating tyrosine residues. This inhibitory phosphorylation blocks the PI3K–Akt cascade before it reaches GLUT4, so even normal insulin concentrations fail to trigger glucose uptake. GLUT4 channels themselves are intact; the problem is upstream signaling. Option D gets the timeline backwards — beta cell failure is a downstream consequence of prolonged resistance, not the initiating event.

Question 3

In type 2 diabetes, inadequate insulin secretion by beta cells is the primary initiating event that causes insulin resistance and hyperglycemia.

• T. True
• F. False

Answer: False

The causal sequence runs in the opposite direction. Insulin resistance — the failure of peripheral tissues to respond to insulin — is the initiating defect. Beta cells compensate by secreting more insulin. Only after years of working at extraordinary capacity do beta cells fail from lipotoxicity and glucotoxicity. By the time type 2 diabetes is diagnosed, patients have typically already lost about 50% of their beta cell mass. Confusing cause and effect here leads to misunderstanding why early type 2 diabetes presents with high (not low) insulin levels.

Question 4

A patient with insulin resistance will typically have elevated fasting insulin levels before they develop elevated fasting glucose.

• T. True
• F. False

Answer: True

This is the compensatory hyperinsulinemia phase. As insulin resistance develops, beta cells increase secretion to overcome the blunted cellular response, maintaining near-normal glucose for years or even decades. During this window, fasting insulin is elevated but fasting glucose remains in the normal range. Standard glucose screening misses these patients entirely. Only when beta cell compensation eventually fails does fasting glucose rise into the prediabetes and diabetes range — which is why insulin levels (or surrogate measures like HOMA-IR) are better early markers of metabolic disease than glucose alone.

Question 5

Why does a patient's normal fasting blood glucose not rule out clinically significant insulin resistance?

Model answer: Normal fasting glucose only means glucose is being cleared adequately — it says nothing about how hard the system is working to achieve that clearance. In insulin resistance, beta cells compensate by secreting far more insulin than normal, maintaining euglycemia despite poor cellular insulin sensitivity. The glucose appears normal because the signal volume has been turned up to compensate for a broken receiver. Only when the beta cells can no longer sustain that compensation — after potentially decades — does glucose rise. Testing insulin levels directly, or calculating HOMA-IR, reveals the underlying pathology.

This is the central clinical insight of early insulin resistance pathophysiology. The disease is present and progressing for years before glucose-based screening detects it. Understanding the compensatory hyperinsulinemia phase explains why lifestyle interventions are far more effective early (when beta cells are intact and resistance can be reversed) than late (after beta cell mass is lost). It also explains why normal glucose should not be falsely reassuring in patients with risk factors like obesity, family history, or acanthosis nigricans.